Milestone Gets China Approval For Etripamil Nasal Spray
Milestone Pharmaceuticals (MIST) announced China's approval of etripamil nasal spray for treating PSVT in adults, triggering a $2M milestone payment. Everest Medicines holds exclusive rights in Greater China, with up to $98M in potential milestones and 18% royalties. The approval was based on Phase 3 study data showing significant efficacy over placebo.
How this was made
The 30-second read
Why it matters
The approval unlocks a $2M milestone and up to $98M in future payments, providing immediate cash and long‑term royalty upside.
Market read
Regulatory clearance in China is a material catalyst for Milestone, likely driving short‑term stock appreciation and long‑term revenue growth.
What to watch
Potential competition from local Chinese manufacturers and regulatory scrutiny on pricing.
Background
Milestone's etripamil (CARDAMYST) is the first US‑approved nasal spray for PSVT; the China approval expands its geographic footprint.
Ticker impact
Milestone Pharmaceuticals received China NMRA approval for its etripamil nasal spray, triggering a $2M milestone payment and eligibility for up to $98M in future milestones.
Expect short‑term upside as investors price in Chinese market entry and future royalty streams.
First‑report approval, sizable upside from China sales, and immediate cash milestone create a clear catalyst.
Market effects
Other cardiac arrhythmia drug developers may see heightened interest in Asian regulatory pathways.
Adds to the pipeline of US biotech firms entering the Chinese market, supporting sector growth in China.
Highlights growing cross‑border collaborations and could influence investor sentiment toward US‑listed biotech stocks.
Counterpoint
Milestone's commercial success depends on pricing and reimbursement in China, which remain uncertain.
Key entities
- CompanyMilestone Pharmaceuticals
US biotech developing etripamil nasal spray.
- CompanyEverest Medicines
Licensee for etripamil in Greater China.
